{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:43:45Z","timestamp":1791413025437,"version":"4.3.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09054-1","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:25:20Z","timestamp":1744197920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and Safety of Nemolizumab in Patients with Prurigo Nodularis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"68","author":[{"given":"Ahsan Raza","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoha Zahid","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"11","key":"9054_CR1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamadermatol.2023.3251","volume":"159","author":"D Rodriguez","year":"2023","unstructured":"Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Lopez ZKJ, Piketty C et al (2023) Patient perspectives on living with severe prurigo nodularis. JAMA Dermatol 159(11):1205","journal-title":"JAMA Dermatol"},{"issue":"10","key":"9054_CR2","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.3390\/ijms25105164","volume":"25","author":"HJ Yook","year":"2024","unstructured":"Yook HJ, Lee JH (2024) Prurigo nodularis: pathogenesis and the Horizon of potential therapeutics. Int J Mol Sci 25(10):5164","journal-title":"Int J Mol Sci"},{"issue":"14","key":"9054_CR3","doi-asserted-by":"publisher","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","volume":"23","author":"Y Shao","year":"2023","unstructured":"Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L et al (2023) Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol 23(14):1301817","journal-title":"Front Immunol"},{"issue":"4","key":"9054_CR4","first-page":"306","volume":"157","author":"G Girolomoni","year":"2022","unstructured":"Girolomoni G, Maurelli M, Gisondi P (2022) The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. Ital J Dermatol Venerol 157(4):306\u2013312","journal-title":"Ital J Dermatol Venerol"},{"issue":"2","key":"9054_CR5","first-page":"28","volume":"1","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Augustin M, Berger T, Elmariah S, Korman NJ, Weisshaar E et al (2020) Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. JAAD Int 1(2):28","journal-title":"JAAD Int"},{"issue":"4","key":"9054_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","volume":"79","author":"E Boozalis","year":"2018","unstructured":"Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S et al (2018) Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 79(4):714","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"9054_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.14722","volume":"46","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Choi J, Sutaria N, Roh YS, Wongvibulsin S, Williams KA et al (2021) Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol 46(7):1277\u20131284","journal-title":"Clin Exp Dermatol"},{"key":"9054_CR8","doi-asserted-by":"publisher","first-page":"105123","DOI":"10.1016\/j.ebiom.2024.105123","volume":"103","author":"H Olbrich","year":"2024","unstructured":"Olbrich H, Kridin K, Hern\u00e1ndez G, Zirpel H, Sadik CD, Terheyden P et al (2024) Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study. eBioMedicine 103:105123","journal-title":"eBioMedicine"},{"issue":"3","key":"9054_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/medicines6030088","volume":"6","author":"KA Whang","year":"2019","unstructured":"Whang KA, Kang S, Kwatra SG (2019) Inpatient burden of prurigo nodularis in the United States. Medicines 6(3):88","journal-title":"Medicines"},{"issue":"3","key":"9054_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","volume":"86","author":"KA Whang","year":"2022","unstructured":"Whang KA, Le TK, Khanna R, Williams KA, Roh YS, Sutaria N et al (2022) Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol 86(3):573\u2013580","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"9054_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/12034754241227808","volume":"28","author":"D Taghaddos","year":"2024","unstructured":"Taghaddos D, Savinova I, Abu-Hilal M (2024) Clinical characteristics and treatment outcomes of prurigo nodularis: a retrospective study. J Cutan Med Surg 28(2):141","journal-title":"J Cutan Med Surg"},{"issue":"9","key":"9054_CR12","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s13555-022-00782-2","volume":"12","author":"A Bewley","year":"2022","unstructured":"Bewley A, Homey B, Pink A (2022) Prurigo nodularis: a review of IL-31RA blockade and other potential treatments. Dermatol Ther 12(9):2039","journal-title":"Dermatol Ther"},{"issue":"10","key":"9054_CR13","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/jdv.18377","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A et al (2022) Nemolizumab effectiveness in prurigo nodularis: onset of action on itch and sleep disturbances. J Euro Acad Dermatol Venereol 36(10):1820\u20135","journal-title":"J Euro Acad Dermatol Venereol"},{"issue":"4","key":"9054_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","volume":"149","author":"LC Tsoi","year":"2021","unstructured":"Tsoi LC, Hacini-Rachinel F, Fogel P, Rousseau F, Xiang X, Patrick MT et al (2021) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol 149(4):1329","journal-title":"J Allergy Clin Immunol"},{"issue":"372","key":"9054_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71","journal-title":"BMJ"},{"issue":"343","key":"9054_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"18","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 18(343):d5928","journal-title":"BMJ"},{"issue":"17","key":"9054_CR17","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D et al (2023) Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 389(17):1579\u20131589","journal-title":"N Engl J Med"},{"issue":"2","key":"9054_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/bjd\/ljae131","volume":"191","author":"H Yokozeki","year":"2024","unstructured":"Yokozeki H, Murota H, Matsumura T, Komazaki H, or the Nemolizumab-JP11 Study Group (2024) Effectiveness and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u2265 13 years. Br J Dermatol 191(2):200\u20138","journal-title":"Br J Dermatol"},{"issue":"8","key":"9054_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J et al (2020) Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 382(8):706\u2013716","journal-title":"N Engl J Med"},{"issue":"2","key":"9054_CR20","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev 18(2):e1230","journal-title":"Campbell Syst Rev"},{"key":"9054_CR21","unstructured":"Dermatology Times [Internet]. 2024 [cited 2024 Oct 22]. FDA Approves Nemolizumab for the Treatment of Prurigo Nodularis. Available from: https:\/\/www.dermatologytimes.com\/view\/fda-approves-nemolizumab-for-the-treatment-of-prurigo-nodularis"},{"issue":"3","key":"9054_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N et al (2021) Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol 84(3):747\u2013760","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"9054_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/CCID.S188070","volume":"28","author":"EH Kowalski","year":"2019","unstructured":"Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT (2019) Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol 28(12):163","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"9054_CR24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","volume":"190","author":"V Liao","year":"2024","unstructured":"Liao V, Cornman HL, Ma E, Kwatra SG (2024) Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol 190(6):798\u2013810","journal-title":"Br J Dermatol"},{"key":"9054_CR25","unstructured":"Dermatology Times [Internet]. 2024 [cited 2024 Oct 22]. Late-Breaking Data: Long-Term Safety and Effectiveness of Largest Prurigo Nodularis Study Ever Conducted. Available from: https:\/\/www.dermatologytimes.com\/view\/late-breaking-data-long-term-safety-and-effectiveness-of-largest-prurigo-nodularis-study-ever-conducted"},{"issue":"1","key":"9054_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","volume":"25","author":"S M\u00fcller","year":"2023","unstructured":"M\u00fcller S, Zeidler C, St\u00e4nder S (2023) Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol 25(1):15","journal-title":"Am J Clin Dermatol"},{"key":"9054_CR27","unstructured":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study - ScienceDirect [Internet]. [cited 2024 Oct 22]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0091674918306985"},{"issue":"1","key":"9054_CR28","doi-asserted-by":"publisher","first-page":"2177096","DOI":"10.1080\/09546634.2023.2177096","volume":"34","author":"K Kabashima","year":"2023","unstructured":"Kabashima K, Matsumura T, Hayakawa Y, Kawashima M, Nemolizumab-JP01 Study Group (2023) Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60\u2009mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial. J Dermatolog Treat 34(1):2177096","journal-title":"J Dermatolog Treat"},{"key":"9054_CR29","unstructured":"Nemolizumab shows long-term effectiveness in treatment of prurigo nodularis, atopic dermatitis [Internet]. [cited 2024 Oct 22]. Available from: https:\/\/www.healio.com\/news\/dermatology\/20240314\/nemolizumab-shows-longterm-effectiveness-in-treatment-of-prurigo-nodularis-atopic-dermatitis"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09054-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:25:23Z","timestamp":1744197923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09054-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9054"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09054-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6009165\/v1","asserted-by":"object"}]},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"27 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"38"}}